Renalytix PLC Notice of GM
03 Avril 2024 - 4:02PM
RNS Regulatory News
RNS Number : 2020J
Renalytix PLC
03 April 2024
Renalytix
plc
("Renalytix" or the "Company")
Notice of
General Meeting
LONDON and SALT LAKE
CITY, April 3, 2024 - Renalytix plc (NASDAQ: RNLX) (LSE:
RENX), an artificial intelligence-enabled in vitro
diagnostics company, focused on optimising clinical management of
kidney disease to drive improved patient outcomes and advance
value-based care, announces that a General Meeting ("GM")
will be held on 22 April 2024 at 3.00 p.m. (BST) at 6 Stratton
Street Mayfair, London W1J 8LD.
A proxy statement (including the
notice of GM) will be posted to shareholders who have not consented
to receive electronic communications later today and is now
available to view on the Company website:
https://investors.renalytix.com/news-and-events/documents-and-presentations
Hard copies of the form of proxy for
the General Meeting will only be available upon request and
instead, voting can be done electronically using the link
www.signalshares.com.
Investors will need to log into their Signal Shares account or
register if they have not previously done so. All details about how
to vote can be found in the notice of GM.
To help with practical arrangements for the GM, any
shareholder wishing to attend is requested to register first by
contacting Walbrook PR via email at renalytix@walbrookpr.com.
For
further information, please contact:
Renalytix
plc
|
www.renalytix.com
|
James McCullough, CEO
|
Via Walbrook PR
|
|
|
Stifel (Nominated
Adviser, Joint Broker)
|
Tel: 020 7710 7600
|
Alex Price / Nicholas Moore / Nick Harland / Samira
Essebiyea
|
|
|
|
Investec Bank plc
(Joint Broker)
|
Tel: 020 7597 4000
|
Gary Clarence / Shalin Bhamra
|
|
|
|
Walbrook PR
Limited
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com
|
Paul McManus / Alice Woodings
|
Mob: 07980 541 893 / 07407
804 654
|
|
|
CapComm
Partners
|
|
Peter DeNardo
|
Tel: 415-389-6400 or investors@renalytix.com
|
|
| |
About
Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro
diagnostics and laboratory services company that is the global
founder and leader in the new field of bioprognosis™ for kidney
health. The leadership team, with a combined 200+ years of
healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment
for rapid progressive decline in kidney function in adult patients
with T2D and early CKD (stages 1-3). We believe that by
understanding how disease will progress, patients and providers can
take action early to improve outcomes and reduce overall health
system costs. For more information, visit www.renalytix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NOGZXLFBZZLBBBB
Renalytix (LSE:RENX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Renalytix (LSE:RENX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024